ReviewFrontiers in pharmacology2025
The therapeutic effect of curcumin in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of animal studies.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is rising sharply, driven by modern lifestyle and dietary changes. As MASLD threatens public health, exploring effective treatments is urgent. Curcumin may benefit MASLD by reducing inflammation and oxidative stress, but evidence reliability remains unclear. This systematic review and meta-analysis aims to evaluate curcumin's effects in MASLD via animal studies. Methods: Relevant animal studies were searched in PubMed, Web of Science, Embase, China National Knowledge Infrastructure (CNKI), and Wanfang Database. Two researchers screened literature and extracted data; discrepancies were resolved via consultation. The SYstematic Review Center for Laboratory animal Experimentation (SYRCLE) risk of bias assessment tool was used to assess methodological quality. Meta-analysis followed the Cochrane Handbook, with analyses via RevMan 5.4 and STATA 15. The study was registered on PROSPERO (CRD42024553149). Results: A total of 22 studies were included, involving 430 animals. Compared with the control group, curcumin significantly reduced alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL) (alleviated dyslipidemia), NAFLD Activity Score (NAS), body weight, liver weight, liver index and inflammatory cytokines (tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6)). It also increased high-density lipoprotein cholesterol (HDL). High heterogeneity was observed for ALT, AST, TC, TG, and HDL. Subgroup analyses showed HDL or LDL heterogeneity was likely associated with curcumin dose. For ALT, AST and LDL, duration might serve as a key regulatory factor contributing to their heterogeneity. Conclusion: Curcumin protected the liver from MASLD via anti-inflammatory, antioxidant, lipid metabolism-regulating, and insulin sensitivity-improving effects, thereby emerging as a therapeutic option for this condition. Limitations include low methodological quality of included studies and potential publication bias. Future research should use rigorous designs, large samples, and long-term studies to confirm efficacy/safety and clarify mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.